Angion Biomedica Corp.

Angion Biomedica Corp. is a biopharmaceutical company specializing in the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate, ANG-3070, is an oral tyrosine kinase receptor inhibitor designed to treat fibrotic diseases, particularly in the kidney and lung. Additionally, Angion Biomedica Corp. develops ANG-3777, a hepatocyte growth factor mimetic for acute organ injuries, ROCK2 inhibitors programs for fibrotic diseases, and a CYP11B2 inhibitor program.

Products

• ANG-3070 (oral tyrosine kinase receptor inhibitor)

• ANG-3777 (hepatocyte growth factor mimetic)

• ROCK2 inhibitors programs

• CYP11B2 inhibitor program